It is a long path from the development of an active pharmaceutical ingredient in the lab to an effective drug – a process that takes several years. Campus companies are often involved in this process on behalf of the pharmaceutical and biotech industry or academic groups.
The company Experimental Pharmacology & Oncology Berlin-Buch (EPO) is a leader in preclinical cancer research in Germany. Worldwide, EPO offers customized and comprehensive service for the preclinical development of novel cancer drugs and is specialized in the development of individualized tumor models.
Q1 Performance Stable despite Oil Price Slump and Corona Expenses. Strong Growth in Radiopharmaceutical Products
Despite heavy burdens from corona and the drop in oil prices, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), a specialist for isotope applications in medicine, science a...more ...
US health authorities to provide USD 6 million in funding for MYELO radiation protection pill
Berlin-based MYELO Therapeutics, an affiliated company of Eckert & Ziegler Strahlen- und Medizintechnik AG, will receive USD 6 million from the National Institutes of Health (NIH) over the next three ...more ...
Eckert & Ziegler Enters TecDAX
The Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) a specialist in isotope-related applications in medicine, science and industry, will enter the TecDAX effec...more ...